DNA-Repair Defects and Olaparib in Metastatic Prostate CancerJoaquı́n Mateo, Johann S. de Bono, Emma Hall et al.|New England Journal of Medicine|2015Cited by 2.2k
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionJane Goodall, Johann S. de Bono, Joaquı́n Mateo et al.|Cancer Discovery|2017Cited by 422
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancerDaniel Nava Rodrigues, Charles G. Drake, Pasquale Rescigno et al.|Journal of Clinical Investigation|2018Cited by 209
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)Jonathan Welti, Johann S. de Bono, Adam Sharp et al.|Clinical Cancer Research|2018Cited by 158
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone SensitivityGunther Boysen, Johann S. de Bono, Daniel Nava Rodrigues et al.|Clinical Cancer Research|2018Cited by 140